Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tim Tristan Hardel

Showing results (1-10 of 7) with videos related to

Pageof 1
Sort By:
Pneumologie (Stuttgart, Germany)|July 27, 2022
Tim Tristan Hardel, Jörn Grensemann
Pneumologie (Stuttgart, Germany)|July 13, 2023
Tim Tristan Hardel, Jörn Grensemann, Stefan Kluge
Deutsche Medizinische Wochenschrift (1946)|March 15, 2022
[Analgesia for ventilation - what's new?]Tim Tristan Hardel, Stephan Braune, Olaf Boenisch, et al.
Leukemia & Lymphoma|July 18, 2014
Prevalence of targetable oncogenic mutations and genomic alterations in Epstein-Barr virus-associated diffuse large B-cell lymphoma of the elderlyNiklas Gebauer, Judith Gebauer, Tim Tristan Hardel, et al.
Anticancer Research|October 3, 2014
Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphomaNiklas Gebauer, Tim Tristan Hardel, Judith Gebauer, et al.
Leukemia & Lymphoma|September 29, 2015
Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell supportNiklas Gebauer, Harald Biersack, Ann-Cathrin Czerwinska, et al.
Leukemia & Lymphoma|May 8, 2015
Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspectiveNiklas Gebauer, Harald Biersack, Ann-Cathrin Czerwinska, et al.
Pageof 1

Showing results (1-10 of 7) with videos related to

Sort By:
Pageof 1
Pneumologie (Stuttgart, Germany)|July 27, 2022
Tim Tristan Hardel, Jörn Grensemann
Pneumologie (Stuttgart, Germany)|July 13, 2023
Tim Tristan Hardel, Jörn Grensemann, Stefan Kluge
Deutsche Medizinische Wochenschrift (1946)|March 15, 2022
[Analgesia for ventilation - what's new?]Tim Tristan Hardel, Stephan Braune, Olaf Boenisch, et al.
Leukemia & Lymphoma|July 18, 2014
Prevalence of targetable oncogenic mutations and genomic alterations in Epstein-Barr virus-associated diffuse large B-cell lymphoma of the elderlyNiklas Gebauer, Judith Gebauer, Tim Tristan Hardel, et al.
Anticancer Research|October 3, 2014
Activating mutations affecting the NF-kappa B pathway and EZH2-mediated epigenetic regulation are rare events in primary mediastinal large B-cell lymphomaNiklas Gebauer, Tim Tristan Hardel, Judith Gebauer, et al.
Leukemia & Lymphoma|September 29, 2015
Single nucleotide polymorphisms in TP53 but not KRAS or MDM2 are predictive of clinical outcome in multiple myeloma treated with high-dose melphalan and autologous stem cell supportNiklas Gebauer, Harald Biersack, Ann-Cathrin Czerwinska, et al.
Leukemia & Lymphoma|May 8, 2015
Favorable prognostic impact of RAS mutation status in multiple myeloma treated with high-dose melphalan and autologous stem cell support in the era of novel agents: a single center perspectiveNiklas Gebauer, Harald Biersack, Ann-Cathrin Czerwinska, et al.
Pageof 1